Live Breaking News & Updates on Telix Chief Medical Officer

Stay updated with breaking news from Telix chief medical officer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU

MELBOURNE, Australia, March 9, 2023 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces presentations from the Company's carbonic anhydrase IX (CAIX) targeting kidney and bladder cancer programs at the 38th Annual European Association of Urology (EAU) Congress to be held in Milan from 10 - 13 March 2023. Further data from Telix's completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118) will be presented in a "Game Changing" oral session. Game Changing sessions are reserved for Phase III trials or other developments that the EAU's Scientific Congress Office believes will have a large impact on daily practice. In addition, presentations will report on the potential utility of TLX250-CDx in urothelial carcinoma or bladder cancer (ZiPUP study, ClinicalTrials.gov Identifier: NCT05046665); and a preclinical evaluation of a ....

Noord Brabant , United States , United Kingdom , Kyahn Williamson , Colin Hayward , Peter Mulders , European Association Of Urology , Telix Pharmaceuticals , Drug Administration , Australian Securities Exchange , University Of Western Australia , Prnewswire Telix Pharmaceuticals Limited , Australian Therapeutic Goods Administration , Corporate Communications , Scientific Congress Office , Health Canada , Pharmaceuticals Limited , Annual European Association , Congress Office , Telix Chief Medical Officer , Professor Peter Mulders , Game Changing , Clinical Trials , Urothelial Cancer Patients , Western Australia , Telix Pharmaceuticals Limited ,

Telix Pharmaceuticals Limited: Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU

MELBOURNE, Australia, March 8, 2023 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations from the Company's carbonic anhydrase IX (CAIX) ....

Noord Brabant , United States , United Kingdom , Dennis Riedl , Kyahn Williamson , Colin Hayward , Peter Mulders , European Association Of Urology , Telix Pharmaceuticals , Drug Administration , Australian Securities Exchange , University Of Western Australia , Prnewswire Telix Pharmaceuticals Limited , Australian Therapeutic Goods Administration , Corporate Communications , Scientific Congress Office , Health Canada , Pharmaceuticals Limited , Annual European Association , Congress Office , Telix Chief Medical Officer , Professor Peter Mulders , Game Changing , Clinical Trials , Urothelial Cancer Patients , Western Australia ,

Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU

/PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations from the Company s carbonic anhydrase IX (CAIX). ....

Noord Brabant , United States , United Kingdom , Kyahn Williamson , Colin Hayward , Peter Mulders , European Association Of Urology , Telix Pharmaceuticals , Drug Administration , Australian Securities Exchange , University Of Western Australia , Prnewswire Telix Pharmaceuticals Limited , Australian Therapeutic Goods Administration , Corporate Communications , Scientific Congress Office , Health Canada , Pharmaceuticals Limited , Annual European Association , Congress Office , Telix Chief Medical Officer , Professor Peter Mulders , Game Changing , Clinical Trials , Urothelial Cancer Patients , Western Australia , Telix Pharmaceuticals Limited ,

ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances

Complete data from global Phase III ZIRCON study of Telix’s investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma. ....

United States , San Francisco , Charlotte Telix , Kyahn Williamson , Colin Hayward , Christian Behrenbruch , Telix Pharmaceuticals , Oliver Sartor Tulane Cancer Center , American Society Of Clinical Oncology , Elshad Hasanov Md Anderson Cancer Center , Drug Administration , Andrei Iagaru Stanford University , Australian Securities Exchange , Australian Therapeutic Goods Administration , Darren Feldman Memorial Sloan Kettering Cancer Center , Corporate Communications , Telix Pharmaceuticals Limited , Health Canada , American Society , Clinical Oncology , Cancers Symposium , Telix Chief Medical Officer , Brian Shuch , Prostate Cancer , Firefly Study , Preliminary Results ,

Telix Pharmaceuticals Limited: ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances

Complete data from global Phase III ZIRCON study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) will be presented at American Society of Clinical ....

United States , United Kingdom , San Francisco , Charlotte Telix , Kyahn Williamson , Colin Hayward , Christian Behrenbruch , Telix Pharmaceuticals , Oliver Sartor Tulane Cancer Center , American Society Of Clinical Oncology , Elshad Hasanov Md Anderson Cancer Center , Drug Administration , Andrei Iagaru Stanford University , Australian Securities Exchange , Prnewswire Telix Pharmaceuticals Limited , Australian Therapeutic Goods Administration , Darren Feldman Memorial Sloan Kettering Cancer Center , Corporate Communications , Health Canada , American Society , Clinical Oncology , Cancers Symposium , Pharmaceuticals Limited , Telix Chief Medical Officer , Brian Shuch , Prostate Cancer ,